Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
about
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Clinical use of Bevacizumab in treating refractory glaucomaShort-Term Topical Bevacizumab in the Treatment of Stable Corneal NeovascularizationEvaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy.Anti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityIntrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.Corneal neovascularization: an anti-VEGF therapy review.Topical Bevacizumab for the Treatment of Ocular Surface Squamous NeoplasiaEmerging roles for antiangiogenesis factors in management of ocular disease.Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model.Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Topical ranibizumab as a treatment of corneal neovascularizationComparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats.Emerging techniques to treat corneal neovascularisationThe association between corneal neovascularization and visual acuity: a systematic review.Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment.Safety of Cultivated Limbal Epithelial Stem Cell Transplantation for Human Corneal Regeneration.Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cellsClinical evaluation and characterisation of corneal vascularisation.Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea.Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.Therapeutic approaches for corneal neovascularization.Anti-vascular endothelial growth factor indications in ocular disease.Corneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P2X2.Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.Update on the Management of High-Risk Penetrating Keratoplasty.Topical bevacizumab treatment in aniridia.Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome.Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.[Yellowish, prominent tumor of the corneal periphery].Corneal angiogenesis based on different protocols of alkaline cauterization in murine models.The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats.Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival.
P2860
Q26823757-1E648009-019F-4DA1-8667-4069EEE2B8DDQ28083405-3E1F93D7-E9AB-44A4-A501-50063F85F0C0Q29999764-BFF1A66E-CA81-46DD-8210-60D132D98798Q33774982-32772751-B802-440C-ABA7-02C385874CD7Q34088274-AA2859A1-7DD0-4604-889B-AF6AAC309352Q34511156-8BBC54E6-8E41-43E4-8EB9-0A05039F66D6Q34641522-6DC42CA5-700F-4AE2-A6AB-82815305714EQ36140280-0109C0BA-CE14-4B86-8A2E-9ED716EDF3E9Q36696513-E6B8EC0C-ACEB-49AF-8BCF-660ABA90D1E2Q36820584-E1FB814B-B1E9-461C-90B0-166E7A58C9D8Q37360910-76533E62-D2DE-49DA-AF8F-C99F3EC2AE92Q37549985-1E4AC77E-45F6-4042-B336-2BA2C43B289CQ37577521-E595D725-A678-4E37-B991-74492A726291Q37721914-19B00441-7E39-4898-A9FC-B2D4A84D249FQ37943247-B3CFF7A3-99B4-4CFA-85B0-8D95F0F63247Q37959022-AE4501E8-75A5-45F5-AC8D-065BC9158006Q38755418-D5D344DF-1C01-454B-8EBA-4E6B672088C8Q38958273-BC64672D-A4A9-449E-9956-1876AB167B83Q39279363-08E22B50-697E-4A46-A511-70008D6A3D84Q39965612-6242FF0B-960B-4DA8-92BB-09B7D9161555Q40018607-1318877C-6FFE-4B36-857B-E91AD2FCD149Q41113827-23038363-4E27-4D79-8FDA-B2B8786446F6Q41423380-2E422398-6B28-43B5-9820-072DF4F78415Q41660636-2EC6DFBB-52BF-4E01-B147-70018FFE6A73Q42206872-A75D393E-1159-4A69-AA62-9E3F298C7090Q43065940-04A47B46-0491-4D25-8431-304DB1366224Q43215465-9F3657D5-42D9-4C20-9DE2-6BE545BEBBF8Q44620936-3452C0BF-9248-40D5-AC74-9CDD267A944CQ47143268-2F1C7112-4376-43AC-BFE0-49FFAA41A04FQ47147918-C7BBF638-8A06-497B-8790-3292CD235CB4Q47266557-41DBDB97-7CAC-44D3-BA70-64AE2A3A1BD5Q47562176-70A6592E-34C3-4384-9D91-C1835FFA5891Q47620917-FDBC713D-9D28-4F06-8C6E-EFBAB4DCD0E9Q47727967-DE2E7509-9887-4446-BB30-E681CB850C7BQ48095945-990CFB25-A907-4B3E-9150-B129E3EB0283Q48268953-CF9A7458-6A31-4FAD-AB98-F8F74B4F12B7Q50100477-F7C8BB39-3D96-4996-86C8-F40FEEFE27EFQ50117870-606DAFFC-A6BB-43F9-850E-BC28235A0188Q51537079-4350E28D-E2C5-48CF-93E2-982CF90F0AA5Q52597776-87442A11-C62E-49F0-9D2F-F6DAF4CE0047
P2860
Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Short- and long-term safety pr ...... st corneal neovascularization.
@en
Short- and long-term safety profile and efficacy of topical bevacizumab
@nl
type
label
Short- and long-term safety pr ...... st corneal neovascularization.
@en
Short- and long-term safety profile and efficacy of topical bevacizumab
@nl
prefLabel
Short- and long-term safety pr ...... st corneal neovascularization.
@en
Short- and long-term safety profile and efficacy of topical bevacizumab
@nl
P2093
P1476
Short- and long-term safety pr ...... st corneal neovascularization.
@en
P2093
Felix Bock
Folkert Horn
Friedrich Kruse
Katja Straub
Yanyan Koenig
P2888
P304
P356
10.1007/S00417-009-1099-1
P577
2009-05-05T00:00:00Z